🚀 Dreaming of a career where you can make a difference? Discover the endless possibilities at NIAID with our #recruitment video. Whether you’re passionate about science, administration, or innovation, there is a place for you. Learn more from some of the dedicated public servants who make NIAID a great place to work: https://lnkd.in/e-sD2kX5 #PSRW #NIAIDCareers
National Institute of Allergy and Infectious Diseases (NIAID)
Government Administration
Rockville, Maryland 44,910 followers
Join NIAID and make a difference!
About us
This is the official LinkedIn account for the National Institute of Allergy and Infectious Diseases (NIAID). NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. Posted comments and images do not necessarily represent the views of NIAID, NIH. Comment Policy: www.niaid.nih.gov/global/comment-policy Privacy Policy: www.niaid.nih.gov/privacy Website: www.niaid.nih.gov
- Website
-
http://www.niaid.nih.gov
External link for National Institute of Allergy and Infectious Diseases (NIAID)
- Industry
- Government Administration
- Company size
- 1,001-5,000 employees
- Headquarters
- Rockville, Maryland
- Type
- Government Agency
Locations
-
Primary
9000 Rockville Pike
Rockville, Maryland 20892, US
Employees at National Institute of Allergy and Infectious Diseases (NIAID)
-
Gail Potter
Deputy Section Chief, Clinical Trials Research Section, at National Institute of Allergy and Infectious Diseases (NIAID)
-
Rodolfo Alarcon
Program Officer at National Institutes of Health/National Institute of Allergy and Infectious Diseases
-
Dave Chen
Senior Visualization Scientist at National Institute of Allergy and Infectious Diseases (NIAID)
-
Michael Mullins
Updates
-
Applications for Intramural NIAID Research Opportunities (INRO) 2025 are being accepted through December 1, 2024. This unique paid #postbaccalaureate opportunity encourages recent grads from underrepresented backgrounds and those committed to diversity to conduct research in NIAID labs in Maryland or Montana. #ApplyNow at https://go.nih.gov/GBHCNbR #NIAIDTraining #INRO2025
-
In the October 16, 2024 #NIAIDFunding News, learn about NIAID’s budget outlook as we begin fiscal year 2025. Understand how we’re improving the availability and effectiveness of our training, fellowship, and career development awards. Read about a new opportunity for novel therapeutics discovery to fight fungal pathogens. Prepare to answer new progress report questions about data management and sharing. Plus, find our answers to reader questions about peer reviewers and awards with multiple principal investigators: https://go.nih.gov/UDpInc5
-
Country-led genetic analysis of samples from the Republic of Congo (RoC) #mpox epidemiologic surveillance system bring new understanding of transmission patterns in the country in early 2024. The analysis was conducted by the RoC Laboratoire National de Santé Publique in Brazzaville with support and scientific partnership from #NIAID and was published in The Lancet. Learn more: https://go.nih.gov/XkwRJoI #MPXV
-
A #NIAID-funded study found #KidneyTransplantation from deceased donors with #HIV to recipients with HIV was safe and comparable to kidney transplantation from donors without HIV. According to the authors, these findings offer evidence to support the expansion of the practice outside of research settings. Learn more: https://go.nih.gov/fSADZhy Johns Hopkins Medicine
-
A #NIAID sponsored clinical trial of an #mpox #vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to interim study results presented at #IDWeek2024. Adolescents are among the population groups affected by mpox in the current Clade I outbreak. The authors underscored the need to evaluate the vaccine in younger children to extend the evidence base to all people affected by mpox. Learn more: https://go.nih.gov/TmlJH9K Baylor College of Medicine Vanderbilt University Medical Center Saint Louis University
-
National Institute of Allergy and Infectious Diseases (NIAID) reposted this
Research shows that the microbiome a baby has at the start of their life affects their microbiome and health as they get older. Babies born via C-section are not exposed to certain microorganisms that could have a positive effect on their long-term health. #NIH_IRP researchers, including National Institute of Allergy and Infectious Diseases (NIAID)'s Dr. Suchitra Hourigan are exploring a new practice that exposes babies born via C-sections to these microorganisms: https://go.nih.gov/LqMMhjA
-
Today is #NationalLatinxAIDSAwareness Day. NIAID and its partners support the #HIV response in Hispanic, Latino, and Latinx communities through research focused on prevention, testing, & treatment resources. Learn more: https://lnkd.in/d2_QUbky #NLAAD Image credit: HIVgov
-
Here is a digest of #NIAID-supported research presentations from Friday, October 11 at #HIVR4P2024. -Two of 11 cisgender women in African countries with #HIV continued to experience viral suppression after pausing the study treatment regimen. Characterizing their immune responses & virus samples could inform HIV science. -HIV Prevention Trials Network (HPTN) found community engagement was key to enrollment and high retention rates for transgender women in a recent #HIVprevention study. -Community stakeholders provided recommendations on how to increase community participation in the development and implementation of #HIVprevention studies in South Africa. -A study in Kalangala District, Uganda demonstrated that it was feasible to train barbers to provide an #HIVprevention intervention. Barbers participating in the intervention scored 100% on knowledge assessments. -After visiting the study site and consulting healthcare providers, several men who initially opposed their female partners’ participation in a study of injectable and oral #HIV pre-exposure prophylaxis decided to support it. -Researchers highlight how the immune responses of newborn monkeys infected with the simian version of #HIV can inform future pediatric HIV #vaccine strategies. -A protein-based #HIV vaccine platform targeting a part of the HIV surface generated a greater immune response than an mRNA-based platform in infant monkeys. -A three-step #HIV immunization strategy rapidly induced immune responses toward development of HIV broadly neutralizing antibodies in mice. -Simian-human immunodeficiency virus (SHIV) infected monkeys showed #HIV broadly neutralizing antibodies similar to the types found in humans. -Laboratory imaging displayed immune responses to particles similar to the simian version of #HIV in monkeys, which could inform the development of novel therapies and vaccines for HIV in people. -Participants in a planned #HIV treatment interruption during a study cited close health monitoring, free sexual health screenings, and being able to restart therapy any time as motivators to enroll. -An #HIV prevention study involving adolescents found sexual health knowledge empowered participants to make informed decisions about options to protect themselves from HIV. -An #HIV #vaccine concept elicited immune responses showing signs of being able to generate HIV broadly neutralizing antibodies in mice with immune systems similar to humans. For full text abstracts, visit the conference program: https://lnkd.in/d9PVgniW #HIVR4P2024 #bNAbs #HIV #HIVprevention #PrEP
-
National Institute of Allergy and Infectious Diseases (NIAID) reposted this
We received outstanding participation and engagement during our recent codeathon to combat antimicrobial resistance (AMR), co-hosted by the National Institute of Allergy and Infectious Diseases (NIAID)! We had 60 participants that formed 10 teams with 10 countries represented. Learn more about their work: https://ow.ly/O22j50TJf12